The Economic Times

Pfizer India speaks up after Karnataka FDA crackdown, says patient safety is top priority

Pfizer India has stated that patient safety and product quality are their top priorities following FDA actions. The Karnataka FDA canceled 16 drug licenses and suspended eight others due to counterfeit drugs. A raid uncovered an illegal operation repacking low-cost medicines as branded drugs, particularly Pfizer products. Pfizer has removed affected batches from the market and is cooperating with authorities in the investigation.